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1. INTRODUCTION {#jcmm14831-sec-0001}
===============

One of the key features of acute myeloid leukaemia (AML), a group of very aggressive myeloid malignancies, is their strikingly heterogenous outcomes.[1](#jcmm14831-bib-0001){ref-type="ref"} Prognostication using clinical and molecular markers is crucial in designing treatment plans. The currently used risk stratification system still has significant intragroup heterogeneity, especially in the intermediate‐risk group.[2](#jcmm14831-bib-0002){ref-type="ref"} Therefore, discovering appropriate biomarkers remains a research hotspot in AML. Over the years, it has been confirmed that *NPM1* and double *CEBPA* mutations are favourable biomarkers, whereas *FLT3‐ITD* mutation is associated with poor prognosis.[3](#jcmm14831-bib-0003){ref-type="ref"}, [4](#jcmm14831-bib-0004){ref-type="ref"}, [5](#jcmm14831-bib-0005){ref-type="ref"} In addition to genetic mutations, aberrant oncogene expressions have also been proposed as a tool for risk stratification. For example, high expressions of *sFRP2* and *DOK7* may suggest better prognosis,[6](#jcmm14831-bib-0006){ref-type="ref"}, [7](#jcmm14831-bib-0007){ref-type="ref"} but high expressions of *FHL2* and *iASPP* may indicate poor survival in AML.[8](#jcmm14831-bib-0008){ref-type="ref"}

DNA damage inducible transcript 4 (DDIT4), also known as REDD1 or RTP801, is induced by various cellular stress conditions, such as hypoxia, endoplasmic reticulum stress, oxidative stress, heat shock and starvation.[9](#jcmm14831-bib-0009){ref-type="ref"} It inhibits the activity of mammalian target of rapamycin complex 1 (mTORC1), a major player in cell growth, proliferation and survival. Abnormally elevated *DDIT4* expression has been found in various malignant tumours.[10](#jcmm14831-bib-0010){ref-type="ref"}, [11](#jcmm14831-bib-0011){ref-type="ref"} Though rapamycin‐derived mTOR inhibitors are powerful drugs in treating cancer, paradoxically, the naturally occurring DDIT4 seems to protect the cancer cells from apoptosis.[10](#jcmm14831-bib-0010){ref-type="ref"}, [12](#jcmm14831-bib-0012){ref-type="ref"}, [13](#jcmm14831-bib-0013){ref-type="ref"} Murine lymphocytes become more sensitive to dexamethasone‐induced cell death after *DDIT4* knockdown.[12](#jcmm14831-bib-0012){ref-type="ref"} Additionally, *DDIT4* promotes gastric cancer proliferation and tumorigenesis through the p53 and MAPK pathways.[14](#jcmm14831-bib-0014){ref-type="ref"}

Recent studies indicated that high *DDIT4* expression is also an adverse factor in AML.[10](#jcmm14831-bib-0010){ref-type="ref"}, [15](#jcmm14831-bib-0015){ref-type="ref"} However, the specific prognostic value of DDIT4 in AML is unknown. We aimed to evaluate the impact of *DDIT4* expression on survival and its associated gene expression patterns in AML patients treated with chemotherapy or transplantation.

2. MATERIALS AND METHODS {#jcmm14831-sec-0002}
========================

2.1. Patients {#jcmm14831-sec-0003}
-------------

The first cohort included 155 de novo AML patients with *DDIT4* expression data, derived from The Cancer Genome Atlas (TCGA) database (<https://cancergenome.nih.gov/>).[16](#jcmm14831-bib-0016){ref-type="ref"} Eighty‐four patients received chemotherapy alone, whereas 71 had allogeneic haematopoietic stem cell transplantation (allo‐HSCT). The baseline clinical and molecular characteristics, follow‐up and survival data were publicly available from TCGA website, including gender, age, white blood cell (WBC) count, bone marrow (BM) and peripheral blood (PB) blast percentages, French‐American‐British (FAB) subtype, karyotype, cytogenetic risk classification, RNA and microRNA sequencing data, and gene mutation spectrum.

The second cohort contained two Gene Expression Omnibus (GEO) datasets, <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE6891> and <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE12417>, including 334 and 162 patients with cytogenetically normal AML (CN‐AML), respectively. This cohort was mainly used to validate the findings of the first cohort. Affymetrix Human Genome 133 plus 2.0 and U133A gene chips were used to obtain gene expression profiles from the <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE6891> and <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE12417> datasets, and the entire process was fully compliant with the standard Affymetrix protocols. All patients' clinical, molecular and microarray data were public accessible in Gene Expression Omnibus ([://www.ncbi.nlm.nih.gov/geo](://www.ncbi.nlm.nih.gov/geo)).

2.2. Statistical analysis {#jcmm14831-sec-0004}
-------------------------

Descriptive statistics were used to summarize the clinical and molecular characteristics of the patients. Datasets were described by median and/or range. Between‐group comparisons of numerical and categorical data were performed by the Mann‐Whitney *U* test and the chi‐square test, respectively. Primary endpoints were event‐free survival (EFS) and overall survival (OS). The former was defined as the time from diagnosis to the first event including relapse, death, failure to achieve complete remission, or was censored at the last follow‐up. The latter was the time from diagnosis to death from any cause, or was censored at the last follow‐up. Between‐group comparisons of OS and EFS were performed by the Kaplan‐Meier method and the log‐rank test. Multivariate Cox proportional hazard models were constructed for OS and EFS using a limited backward elimination procedure. Spearman rank correlation was used to determine the associations between gene expression profile and *DDIT4* expression. Multiple testing errors were assessed by false discovery rate (FDR). Gene Ontology (GO) enrichment analysis was conducted to assess enrichment of gene expression products associated with DDIT4. All tests were two‐tailed. Statistical significance was defined as *P* \< .05. All statistical analyses were performed by R software 3.5.0, SPSS software 24.0 and GraphPad Prism software 7.0.

3. RESULTS {#jcmm14831-sec-0005}
==========

3.1. Differences in clinical and molecular characteristics between different *DDIT4* expression groups {#jcmm14831-sec-0006}
------------------------------------------------------------------------------------------------------

In order to evaluate the prognostic significance of DDIT4 in AML, the first cohort was divided into the chemotherapy‐only group and the allo‐HSCT group. Within each group, the respective median *DDIT4* expression level was used to divide the group into high and low expression subgroups, and the clinical and molecular characteristics of subgroups were compared (Table [1](#jcmm14831-tbl-0001){ref-type="table"}).

###### 

Clinical and molecular characteristics of patients in different treatment groups

  Characteristics                Chemotherapy‐only group   Allo‐HSCT group                                                                                          
  ------------------------------ ------------------------- ------------------ ----------------------------------------------- ------------------ ------------------ -----------------------------------------------
  Age/years, median (range)      70 (35‐88)                63 (22‐82)         .003[a](#jcmm14831-note-0003){ref-type="fn"}    53 (18‐72)         50 (21‐65)         .411[a](#jcmm14831-note-0003){ref-type="fn"}
  Age group/n (%)                                                                                                                                                   
  \<60 y                         8 (19.0)                  18 (42.9)          .018[b](#jcmm14831-note-0004){ref-type="fn"}    23 (65.7)          29 (80.6)          .158[b](#jcmm14831-note-0004){ref-type="fn"}
  ≥60 y                          34 (81.0)                 24 (57.1)                                                          12 (34.3)          7 (19.4)            
  Gender/n (%)                                                                                                                                                      
  Male                           25 (59.5)                 20 (47.6)          .274[b](#jcmm14831-note-0004){ref-type="fn"}    20 (57.1)          21 (58.3)          .919[b](#jcmm14831-note-0004){ref-type="fn"}
  Female                         17 (40.5)                 22 (52.4)                                                          15 (42.9)          15 (41.7)           
  WBC/×10^9^/L, median (range)   13.3 (1.0‐297.4)          16.1 (0.7‐171.9)   .522[a](#jcmm14831-note-0003){ref-type="fn"}    34.2 (0.6‐223.8)   29.4 (0.9‐115.4)   .761[a](#jcmm14831-note-0003){ref-type="fn"}
  BM blast/%, median (range)     77 (32‐99)                66 (30‐95)         .041[a](#jcmm14831-note-0003){ref-type="fn"}    72 (30‐100)        70 (34‐99)         .913[a](#jcmm14831-note-0003){ref-type="fn"}
  PB blast/%, median (range)     22 (0‐98)                 25 (0‐91)          .449[a](#jcmm14831-note-0003){ref-type="fn"}    53 (0‐96)          45 (0‐94)          .366[a](#jcmm14831-note-0003){ref-type="fn"}
  FAB subtypes/n (%)                                                                                                                                                
  M0                             7 (16.7)                  0 (0.0)            .012[b](#jcmm14831-note-0004){ref-type="fn"}    4 (11.4)           5 (13.9)           .755[b](#jcmm14831-note-0004){ref-type="fn"}
  M1                             10 (23.8)                 10 (23.8)          1.000[b](#jcmm14831-note-0004){ref-type="fn"}   17 (48.6)          6 (16.7)           .004[b](#jcmm14831-note-0004){ref-type="fn"}
  M2                             7 (16.7)                  14 (33.3)          .078[b](#jcmm14831-note-0004){ref-type="fn"}    9 (25.7)           9 (25.0)           1.000[b](#jcmm14831-note-0004){ref-type="fn"}
  M3                             0 (0.0)                   0 (0.0)            1.000[b](#jcmm14831-note-0004){ref-type="fn"}   0 (0.0)            1 (2.8)            .493[b](#jcmm14831-note-0004){ref-type="fn"}
  M4                             8 (19.0)                  12 (28.6)          .306[b](#jcmm14831-note-0004){ref-type="fn"}    1 (2.9)            12 (33.3)          .001[b](#jcmm14831-note-0004){ref-type="fn"}
  M5                             6 (14.3)                  6 (14.3)           1.000[b](#jcmm14831-note-0004){ref-type="fn"}   2 (5.7)            2 (5.6)            1.000[b](#jcmm14831-note-0004){ref-type="fn"}
  M6                             1 (2.4)                   0 (0.0)            1.000[b](#jcmm14831-note-0004){ref-type="fn"}   1 (2.9)            0 (0.0)            .493[b](#jcmm14831-note-0004){ref-type="fn"}
  M7                             3 (7.1)                   0 (0.0)            .241[b](#jcmm14831-note-0004){ref-type="fn"}    1 (2.9)            1 (2.8)            1.000[b](#jcmm14831-note-0004){ref-type="fn"}
  Cytogenetics/n (%)                                                                                                                                                
  Normal                         19 (45.2)                 21 (50.0)          .662[b](#jcmm14831-note-0004){ref-type="fn"}    18 (51.4)          15 (41.7)          .410[b](#jcmm14831-note-0004){ref-type="fn"}
  Complex karyotype              9 (21.4)                  2 (4.8)            .048[b](#jcmm14831-note-0004){ref-type="fn"}    9 (25.7)           2 (5.6)            .019[b](#jcmm14831-note-0004){ref-type="fn"}
  8 Trisomy                      0 (0.0)                   0 (0.0)            1.000[b](#jcmm14831-note-0004){ref-type="fn"}   3 (8.6)            3 (8.3)            1.000[b](#jcmm14831-note-0004){ref-type="fn"}
  inv(16)/CBFβ‐MYH11             0 (0.0)                   6 (14.3)           .026[b](#jcmm14831-note-0004){ref-type="fn"}    0 (0.0)            5 (13.9)           .054[b](#jcmm14831-note-0004){ref-type="fn"}
  11q23/MLL                      1 (2.4)                   2 (4.8)            .614[b](#jcmm14831-note-0004){ref-type="fn"}    1 (2.9)            2 (5.6)            1.000[b](#jcmm14831-note-0004){ref-type="fn"}
  −7/7q‐                         2 (4.8)                   1 (2.4)            .614[b](#jcmm14831-note-0004){ref-type="fn"}    2 (5.7)            1 (2.8)            .614[b](#jcmm14831-note-0004){ref-type="fn"}
  t(15;17)/PML‐RARA              0 (0.0)                   0 (0.0)            1.000[b](#jcmm14831-note-0004){ref-type="fn"}   0 (0.0)            1 (2.8)            1.000[b](#jcmm14831-note-0004){ref-type="fn"}
  t(9;22)/BCR‐ABL1               1 (2.4)                   0 (0.0)            1.000[b](#jcmm14831-note-0004){ref-type="fn"}   1 (2.9)            1 (2.8)            1.000[b](#jcmm14831-note-0004){ref-type="fn"}
  t(8;21)/RUNX1‐RUNX1T1          0 (0.0)                   6 (14.3)           .026[b](#jcmm14831-note-0004){ref-type="fn"}    0 (0.0)            1 (2.8)            1.000[b](#jcmm14831-note-0004){ref-type="fn"}
  Others                         10 (23.8)                 4 (9.5)            .079[b](#jcmm14831-note-0004){ref-type="fn"}    1 (2.9)            5 (13.9)           .199[b](#jcmm14831-note-0004){ref-type="fn"}
  Risk/n (%)                                                                                                                                                        
  Good                           0 (0.0)                   12 (28.6)          .000[b](#jcmm14831-note-0004){ref-type="fn"}    0 (0.0)            7 (19.4)           .011[b](#jcmm14831-note-0004){ref-type="fn"}
  Intermediate                   26 (61.9)                 20 (47.6)          .188[b](#jcmm14831-note-0004){ref-type="fn"}    19 (54.3)          21 (58.3)          .731[b](#jcmm14831-note-0004){ref-type="fn"}
  Poor                           16 (38.1)                 10 (23.8)          .157[b](#jcmm14831-note-0004){ref-type="fn"}    16 (45.7)          8 (22.2)           .036[b](#jcmm14831-note-0004){ref-type="fn"}
  *FLT3‐ITD*/n (%)                                                                                                                                                  
  Positive                       6 (14.3)                  9 (21.4)           .393[b](#jcmm14831-note-0004){ref-type="fn"}    9 (25.7)           8 (22.2)           .730[b](#jcmm14831-note-0004){ref-type="fn"}
  Negative                       36 (85.7)                 33 (78.6)                                                          26 (74.3)          28 (77.8)           
  *NPM1*/n (%)                                                                                                                                                      
  Mutation                       13 (31.0)                 14 (13.3)          .815[b](#jcmm14831-note-0004){ref-type="fn"}    9 (25.7)           9 (25.0)           .945[b](#jcmm14831-note-0004){ref-type="fn"}
  Wild type                      29 (69.0)                 28 (66.7)                                                          26 (74.3)          27 (75.0)           
  *DNMT3A*/n (%)                                                                                                                                                    
  Mutation                       12 (28.6)                 11 (26.2)          .807[b](#jcmm14831-note-0004){ref-type="fn"}    10 (28.6)          7 (19.4)           .368[b](#jcmm14831-note-0004){ref-type="fn"}
  Wild type                      30 (71.4)                 31 (73.8)                                                          25 (71.4)          29 (80.6)           
  *IDH1*/*IDH2*/n (%)                                                                                                                                               
  Mutation                       9 (21.4)                  6 (14.3)           .393[b](#jcmm14831-note-0004){ref-type="fn"}    11 (31.4)          6 (16.7)           .145[b](#jcmm14831-note-0004){ref-type="fn"}
  Wild type                      33 (78.6)                 36 (85.7)                                                          24 (68.6)          30 (83.3)           
  *RUNX1*/n (%)                                                                                                                                                     
  Mutation                       12 (28.6)                 2 (4.8)            .003[b](#jcmm14831-note-0004){ref-type="fn"}    3 (8.6)            5 (13.9)           .710[b](#jcmm14831-note-0004){ref-type="fn"}
  Wild type                      30 (71.4)                 42 (95.2)                                                          32 (91.4)          31 (86.1)           
  *NRAS/KRAS*/n (%)                                                                                                                                                 
  Mutation                       6 (14.3)                  6 (14.3)           1.000[b](#jcmm14831-note-0004){ref-type="fn"}   1 (2.9)            6 (16.7)           .107[b](#jcmm14831-note-0004){ref-type="fn"}
  Wild type                      36 (85.7)                 36 (85.7)                                                          34 (97.1)          30 (83.3)           
  *TET2*/n (%)                                                                                                                                                      
  Mutation                       4 (9.5)                   7 (16.7)           .332[b](#jcmm14831-note-0004){ref-type="fn"}    0 (0.0)            4 (11.1)           .115[b](#jcmm14831-note-0004){ref-type="fn"}
  Wild type                      38 (90.5)                 35 (83.3)                                                          35 (100)           32 (88.9)           
  *TP53*/n (%)                                                                                                                                                      
  Mutation                       9 (21.4)                  2 (4.8)            .024[b](#jcmm14831-note-0004){ref-type="fn"}    3 (8.6)            1 (2.8)            .357[b](#jcmm14831-note-0004){ref-type="fn"}
  Wild type                      33 (78.6)                 40 (95.2)                                                          32 (91.4)          35 (97.2)           

Abbreviations: BM, bone marrow; FAB, French‐American‐British; PB, peripheral blood; WBC, white blood cell.

Denotes Mann‐Whitney *U* test

Denotes chi‐square test.
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In the chemotherapy‐only group, compared with the *DDIT4* ^low^ subgroup, the *DDIT4* ^high^ subgroup had more patients ≥60 years old (*P* = .018), FAB‐M0 (*P* = .012), with complex karyotype (*P* = .048), more frequent *TP53* and *RUNX1* mutations (*P* = .024, *P* = .003, respectively), and higher BM blast percentage (*P* = .041). It had fewer patients with *CBFβ‐MYH11* or *RUNX1‐RUNX1T1* (all *P* = .026) or good cytogenetic risk (*P* \< .001). Gender distribution, WBC count, PB blast percentage and the frequencies of other recurrent genetic mutations (*NPM1*, *FLT3*, *NRAS/KRAS*, *IDH1/IDH2*, *DNMT3A* and *TET2*) were similar in the two subgroups.

In the allo‐HSCT group, compared with the *DDIT4* ^low^ subgroup, the *DDIT4* ^high^ subgroup had more patients with FAB‐M1 (*P* = .004), complex karyotype (*P* = .019) and poor cytogenetic risk (*P* = .036), yet fewer patients with FAB‐M4 (*P* = .001) or good cytogenetic risk (*P* = .011). Age, gender distribution, WBC count, BM/PB blast percentage and the frequencies of recurrent gene mutations (*NPM1*, *FLT3*, *RUNX1*, *DNMT3A*, *NRAS/KRAS*, *IDH1/IDH2*, *TP53* and *TET2*) were not statistically different between the two subgroups.

3.2. Prognostic value of *DDIT4* expression in AML {#jcmm14831-sec-0007}
--------------------------------------------------

In the TCGA cohort, high *DDIT4* expressers generally had significantly shorter OS and EFS than the low expressers (all *P* \< .001; Figure [1](#jcmm14831-fig-0001){ref-type="fig"}A,B). Then, patients were further stratified according to the treatment modality and the median *DDIT4* expression levels in the different treatment subgroups. For the high expressors (n = 77), those treated with allo‐HSCT had significantly better survival than those who received chemotherapy alone (all *P* \< .01, Figure [1](#jcmm14831-fig-0001){ref-type="fig"}C,D). For the low expressors (n = 78), treatment modality did not have outstanding influence on survival (all *P* \> .05, Figure [1](#jcmm14831-fig-0001){ref-type="fig"}C,D). Kaplan‐Meier analysis demonstrated that in the chemotherapy‐only group, high *DDIT4* expressers had significantly shorter OS and EFS than the low expressers (all *P* \< .001, Figure [2](#jcmm14831-fig-0002){ref-type="fig"}A,B), whereas the survival was similar in the high and low expressors of the allo‐HSCT group (all *P* \> .05, Figure [2](#jcmm14831-fig-0002){ref-type="fig"}C,D).

![Kaplan‐Meier curves of event‐free survival (EFS) and overall survival (OS) in the first cohort. (A,B) In the entire cohort, high *DDIT4* expressers had shorter EFS and OS than the low expressers. (C,D) In the *DDIT4* ^high^ group, patients treated with allo‐HSCT had longer OS and EFS than those who received chemotherapy only. In the *DDIT4* ^low^ group, there were no significant differences in OS and EFS between different treatment groups](JCMM-24-1067-g001){#jcmm14831-fig-0001}

![Kaplan‐Meier curves of event‐free survival (EFS) and overall survival (OS) in the chemotherapy‐only and allo‐HSCT groups. (A,B) In the chemotherapy group, high *DDIT4* expressers had shorter OS and EFS than the low expressers. (C,D) In the allo‐HSCT group, there were no significant differences in EFS and OS between high and low *DDIT4* expression groups](JCMM-24-1067-g002){#jcmm14831-fig-0002}

3.3. Multivariate analysis of possible prognostic factors {#jcmm14831-sec-0008}
---------------------------------------------------------

To examine whether the impact of *DDIT4* expression on AML survival was independent, we constructed multivariate Cox proportional hazard models using multiple variables, including *DDIT4* expression (high vs low), WBC count (≥15 vs \<15 × 10^9^/L), age (≥60 vs \<60 years), BM blasts (≥70 vs \<70%), PB blasts (≥20 vs \<20%), *NPM1* (mutated vs wild), *DNMT3A* (mutated vs wild), *TET2* (mutated vs wild), *TP53* (mutated vs wild) and *FLT3‐ITD* (positive vs negative) (Table [2](#jcmm14831-tbl-0002){ref-type="table"}).

###### 

Multivariate analysis of EFS and OS in different treatment groups

  Variables                           EFS                    OS                           
  ----------------------------------- ---------------------- ------ --------------------- ------
  Chemotherapy‐only group                                                                 
  *DDIT4* (high vs Low)               1.940 (1.158‐3.251)    .012   1.878 (1.118‐3.155)   .017
  Age (≥60 vs \<60 y)                 3.051 (1.636‐5.688)    .000   2.763 (1.478‐5.167)   .001
  WBC count (≥15 vs \<15 × 10^9^/L)   1.470 (0.816‐2.646)    .199   1.407 (0.795‐2.490)   .241
  BM blasts (≥70 vs \<70%)            1.863 (1.054‐3.293)    .032   1.804 (1.025‐3.176)   .041
  PB blasts (≥20 vs \<20%)            0.928 (0.548‐1.571)    .781   0.868 (0.507‐1.487)   .606
  *FLT3‐ITD* (positive vs negative)   1.245 (0.635‐2.442)    .523   1.183 (0.582‐2.408)   .642
  *NPM1* (mutated vs wild)            0.947 (0.491‐1.826)    .871   0.772 (0.401‐1.488)   .440
  *DNMT3A* (mutated vs wild)          1.704 (0.979‐2.965)    .059   1.772 (1.033‐3.042)   .038
  *TET2* (mutated vs wild)            0.943 (0.429‐2.074)    .885   0.672 (0.309‐1.460)   .315
  *TP53* (mutated vs wild)            3.006 (1.372‐6.587)    .006   2.444 (1.135‐5.261)   .022
  Allo‐HSCT                                                                               
  *DDIT4* (high vs Low)               0.995 (0.557‐1.775)    .985   1.622 (0.875‐3.004)   .124
  Age (≥60 vs \<60 y)                 1.097 (0.546‐2.204)    .796   1.404 (0.710‐2.777)   .330
  WBC count (≥15 vs \<15 × 10^9^/L)   1.918 (1.032‐3.563)    .039   1.537 (0.794‐2.975)   .202
  BM blasts (≥70 vs \<70%)            0.777 (0.420‐1.437)    .421   0.782 (0.391‐1.566)   .488
  PB blasts (≥20 vs \<20%)            1.235 (0.633‐2.408)    .536   1.445 (0.695‐3.005)   .325
  *FLT3‐ITD* (positive vs negative)   2.462 (1.209‐5.015)    .013   2.354 (1.048‐5.291)   .038
  *NPM1* (mutated vs wild)            0.636 (0.312‐1.298)    .213   0.625 (0.277‐1.409)   .257
  *DNMT3A* (mutated vs wild)          1.177 (0.605‐2.292)    .631   1.377 (0.691‐2.743)   .363
  *TET2* (mutated vs wild)            0.516 (0.145‐1.838)    .307   0.961 (0.267‐3.452)   .951
  *TP53* (mutated vs wild)            3.046 (0.884‐10.495)   .078   7.196 (1.871‐27.67)   .004

Abbreviations: BM, bone marrow; CI, confidence interval; EFS, Event‐free survival; HR, hazard ratio; OS, Overall survival; PB, peripheral blood; WBC, white blood cell.
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In the chemotherapy‐only group, high *DDIT4* expression was an independent risk factor for both EFS and OS, along with age ≥ 60, BM blasts ≥ 70% and *TP53* mutation (all *P* \< .05). In addition, *DNMT3A* mutation was an independent risk factor for OS (*P* = .038). In the allo‐HSCT group, *FLT3‐ITD* was an independent risk factor for OS and EFS (all *P* \< .05), and WBC count ≥ 15 × 10^9^/L and *TP53* mutation were independent risk factors for EFS (*P* = .039) and OS (*P* = .004), respectively, but *DDIT4* expression was not an independent factor for survival.

3.4. Associations between genome‐wide gene expression profile and *DDIT4* expression {#jcmm14831-sec-0009}
------------------------------------------------------------------------------------

To elucidate the possible mechanism for the influence of *DDIT4* in AML, *DDIT4*‐associated gene expression profiles were summarized utilizing the high‐throughput sequencing information from TCGA database. Three hundred and sixty‐eight up‐regulated and 171 down‐regulated genes that were significantly associated with *DDIT4* expression (*P* \< .05, fold change = 1.5, Figure [3](#jcmm14831-fig-0003){ref-type="fig"}A) were screened. Eventually, with a more rigorous analysis (fold change = 2), 359 genes were excluded, and the remaining 180 genes were depicted in an aberrant expression heatmap (Figure [3](#jcmm14831-fig-0003){ref-type="fig"}B). Many leukaemia‐associated genes were positively associated with *DDIT4* expression, including *WNT9A*, *NOTCH3*, *SOCS1*, *MCL1*, *HIF1A*, *ALOX5*, *CD47*, *CXCR4*, *CDK9*, *HRAS*, *PLK3* and *ETS2*. However, *RPL5*, a tumour suppressor in multiple cancers, was negatively correlated with *DDIT4* expression. Furthermore, GO enrichment analysis suggested that the genes related to *DDIT4* expression were mainly concentrated in \"acute and chronic myeloid leukaemia,\" \"bladder cancer,\" \"hedgehog signalling pathway,\" \"endometrial cancer,\" and \"basal cell carcinoma\" signalling pathways (Figure [3](#jcmm14831-fig-0003){ref-type="fig"}C).

![Genome‐wide gene expression profile and cell signalling pathways associated with *DDIT4* expression. (A) Volcano plot of differential gene expression. Up‐regulated and down‐regulated genes were labelled with red and green dots, respectively. (B) Heatmap of genes related to *DDIT4* expression. (C) Gene ontology (GO) enrichment analysis of genes related to *DDIT4* expression](JCMM-24-1067-g003){#jcmm14831-fig-0003}

3.5. Validation of the prognostic value of DDIT4 expression in AML {#jcmm14831-sec-0010}
------------------------------------------------------------------

In the two other large CN‐AML cohorts from the GEO database, high *DDIT4* expression was also related to significantly shorter OS. Combining the data with the TCGA cohort, results consistently showed that up‐regulated expression of *DDIT4* had deleterious effect on survival of AML patient (all *P* \< .01, Figure [4](#jcmm14831-fig-0004){ref-type="fig"}).

![Validation of the prognostic value of *DDIT4* expression in the second cohort. High *DDIT4* expressers had shorter OS than the low expressers in two independent databases, and the combined data analysis showed the same result](JCMM-24-1067-g004){#jcmm14831-fig-0004}

4. DISCUSSION {#jcmm14831-sec-0011}
=============

In this retrospective study, we demonstrated that up‐regulated *DDIT4* expression adversely affects the prognosis of AML patients who underwent chemotherapy alone, but not those who were treated with allo‐HSCT, suggesting that allo‐HSCT may neutralize its negative prognostic impact. Patients with low *DDIT4* expression, on the other hand, had no survival benefit from allo‐HSCT in the study.

Dysregulated *DDIT4* expression is seen in various cancers and its role in tumorigenesis is likely tumour‐dependent, based on previous studies.[17](#jcmm14831-bib-0017){ref-type="ref"}, [18](#jcmm14831-bib-0018){ref-type="ref"}, [19](#jcmm14831-bib-0019){ref-type="ref"} In breast cancer, *DDIT4* is a tumour suppressor against miR‐495‐mediated oncogenesis and hypoxia resistance.[20](#jcmm14831-bib-0020){ref-type="ref"} In ovarian cancer, on the other hand, it is positively correlated with the oncogene p‐AKT and predicts late FIGO stage and serous adenocarcinoma,[13](#jcmm14831-bib-0013){ref-type="ref"} indicating its role as a tumour promotor. DDIT4 is heavily involved in the PI3K‐Akt‐mTOR signalling pathway, a crucial pathway that regulates cell growth, motility, proliferation, apoptosis and one of the most commonly altered pathways in cancer.[21](#jcmm14831-bib-0021){ref-type="ref"} It is a downstream effector of PI3K‐Akt‐mTOR. By collaborating with other proteins, it is responsible for prostate cancer cells' invasive behaviour.[22](#jcmm14831-bib-0022){ref-type="ref"} Moreover, DDIT4 also participates in the RAS signalling pathway and highlights the complex crosstalk among different cellular signalling pathways. Overexpression of *DDIT4* after activation of RAS oncogene in RAS‐transformed human ovarian epithelial cells can promote cell proliferation and colony formation, enhance the expression of anti‐apoptotic proteins and reduce the expression of pro‐apoptotic proteins.[19](#jcmm14831-bib-0019){ref-type="ref"}, [23](#jcmm14831-bib-0023){ref-type="ref"} In our study, high *DDIT4* expression coexisted with other established poor prognostic factors, such as old age, complex karyotype and *TP53* mutation, and did not coexist with other well‐known favourable prognostic factors, such as *CBFβ‐MYH11* and *RUNX1‐RUNX1T*. As an independent adverse prognostic factor in AML patients who received chemotherapy alone, *DDIT4* up‐regulation likely plays a positive role in leukaemogenesis.

Moreover, we found that enhanced *DDIT4* expression was also an independent poor prognostic factor in CN‐AML patients with a relatively consistent cytogenetic background. GO analysis demonstrated that genes (*WNT9A*, *NOTCH3*, *SOCS1*, *MCL1*, *HIF1A*, *ALOX5*, *CD47*, *CXCR4*, *CDK9*, *HRAS*, *PLK3*, *ETS2* and *RPL5*) involved in "acute and chronic myeloid leukaemia," "bladder cancer," "hedgehog signalling pathway," "endometrial cancer" and "basal cell carcinoma" signalling pathways were significantly correlated with the *DDIT4* expression. Pinto et al observed a significant positive correlation between *DDIT4* and *NOTCH1* expression, and both of them tend to highly express in high‐risk AML patients.[24](#jcmm14831-bib-0024){ref-type="ref"} These results indicate that *DDIT4* expression may explain some of the aggressive features of AML by involving in the above pathways, though the exact role of *DDIT4* in leukaemogenesis requires further study.

Multivariate analysis of the chemotherapy‐only group was consistent with previous studies in that older age (≥60 years), more BM blasts (≥70%), mutations in *TP53* and *DNMT3A* also independently contributed to shorter EFS and OS.[25](#jcmm14831-bib-0025){ref-type="ref"}, [26](#jcmm14831-bib-0026){ref-type="ref"}, [27](#jcmm14831-bib-0027){ref-type="ref"}, [28](#jcmm14831-bib-0028){ref-type="ref"} The effect of high *DDIT4* expression on survival was not reproduced in the allo‐HSCT group, whereas WBC count ≥ 15 × 10^9^/L, *FLT3‐ITD* and *TP53* mutation were associated with poor OS or EFS, suggesting that allo‐HSCT could ameliorate the adverse prognostic effect of high *DDIT4* expression in AML. Patients with high *DDIT4* expression benefited more from allo‐HSCT, whereas survival was not affected by treatment modality in the low expressers. Therefore, allo‐HSCT may be a better option for patients with high *DDIT4* expression, but may be not necessary for patients with low *DDIT4* expression.

To summarize, our results indicated that enhanced *DDIT4* expression could be a poor prognostic factor for AML patients treated with chemotherapy alone, and these patients might benefit from allo‐HSCT. We were able to identify a unique gene expression pattern and cell signalling pathways associated with *DDIT4* expression, which could shed lights on the role of *DDIT4* in leukaemogenesis. It is reasonable to envision it as a marker for risk stratification and guidance for treatment in AML. Our study was limited by its small, retrospective nature, and the results would need to be verified by a larger prospective population.
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